SenesTech Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

SenesTech wird ein Gewinn- und Umsatzwachstum von 15.6% bzw. 44% pro Jahr prognostiziert, während der Gewinn pro Aktie um 56.7% pro Jahr wachsen soll.

Wichtige Informationen

15.6%

Wachstumsrate der Gewinne

56.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	44.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think SenesTech (NASDAQ:SNES) Needs To Drive Business Growth Carefully

Aug 24

SenesTech EPS of -$0.56

Nov 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:SNES - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	8	-6	-4	N/A	1
12/31/2025	5	-7	-6	N/A	1
12/31/2024	2	-7	-7	N/A	1
3/31/2024	1	-8	-8	-7	N/A
12/31/2023	1	-8	-8	-8	N/A
9/30/2023	1	-8	-8	-8	N/A
6/30/2023	1	-9	-8	-8	N/A
3/31/2023	1	-9	-9	-9	N/A
12/31/2022	1	-10	-9	-9	N/A
9/30/2022	1	-10	-8	-8	N/A
6/30/2022	1	-10	-8	-8	N/A
3/31/2022	1	-9	-8	-8	N/A
12/31/2021	1	-8	-8	-8	N/A
9/30/2021	1	-8	-8	-8	N/A
6/30/2021	0	-8	-8	-8	N/A
3/31/2021	0	-7	-7	-7	N/A
12/31/2020	0	-8	-7	-7	N/A
9/30/2020	0	-9	-8	-7	N/A
6/30/2020	0	-10	-8	-8	N/A
3/31/2020	0	-10	-8	-8	N/A
12/31/2019	0	-10	-8	-8	N/A
9/30/2019	0	-10	-8	-8	N/A
6/30/2019	0	-10	-9	-8	N/A
3/31/2019	0	-12	-9	-9	N/A
12/31/2018	0	-12	-9	-9	N/A
9/30/2018	0	-12	-9	-9	N/A
6/30/2018	0	-12	-8	-8	N/A
3/31/2018	0	-11	-9	-8	N/A
12/31/2017	0	-12	N/A	-9	N/A
9/30/2017	0	-14	N/A	-10	N/A
6/30/2017	0	-13	N/A	-10	N/A
3/31/2017	0	-12	N/A	-9	N/A
12/31/2016	0	-11	N/A	-7	N/A
9/30/2016	0	-14	N/A	-5	N/A
6/30/2016	0	-20	N/A	-4	N/A
3/31/2016	0	-20	N/A	-4	N/A
12/31/2015	0	-18	N/A	-4	N/A
12/31/2014	0	-7	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SNES wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SNES wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SNES wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SNESDie Einnahmen des Unternehmens (44% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: SNESDie Einnahmen des Unternehmens (44% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SNES in 3 Jahren voraussichtlich hoch sein wird

SenesTech Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 67%

Consensus EPS estimates upgraded to US$0.66 loss

No longer forecast to breakeven

Price target decreased to US$4.00

Price target decreased to US$4.00

Consensus forecasts updated

Recent updates

SenesTech, Inc., Annual General Meeting, Jul 11, 2024

Consensus EPS estimates fall by 67%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

SenesTech, Inc. to Report Q1, 2024 Results on May 09, 2024

Nasdaq Determines SenesTech Eligible for an Additional 180 Calendar Day Period, or Until August 19, 2024, to Regain Compliance with the Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.66 loss

New major risk - Financial position

SenesTech, Inc. to Report Q4, 2023 Results on Feb 21, 2024

SenesTech Partners with Global Leader in Irrigation Solutions to Expand Evolve Soft Bait to Open Field Agriculture Applications

SenesTech's ContraPest Registered for Use in Puerto Rico to Combat Rat Infestations

SenesTech, Inc. has completed a Follow-on Equity Offering.

New major risk - Financial position

SenesTech, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

SenesTech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

SenesTech, Inc. to Report Q3, 2023 Results on Nov 09, 2023

SenesTech Taking Orders for Evolve™ Soft Bait for Rodent Fertility Control

SenesTech, Inc. Launches Evolve Soft Bait for Rodent Fertility Control

New minor risk - Share price stability

SenesTech Receives Non-Compliance Letter from Nasdaq

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

SenesTech, Inc. to Report Q2, 2023 Results on Aug 10, 2023

SenesTech, Inc. Launches Isolate Bait System for Contrapest

First quarter 2023 earnings: EPS and revenues miss analyst expectations

SenesTech, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Full year 2022 earnings released: US$0.016 loss per share (vs US$14.78 loss in FY 2021)

Senestech Names Nicole Williams as Chief Revenue Officer

Price target decreased to US$4.00

SenesTech, Inc. Announces Executive Changes

SenesTech, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SenesTech Announces Resignation of K.C. Kavanagh as Member of Board of Directors

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

SenesTech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

SenesTech, Inc. Announces its New Elevate Bait System with ContraPest Now Available in California

SenesTech, Inc. Announces its New Elevate Bait System with ContraPest Available for Sale

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

SenesTech, Inc. to Report Q1, 2022 Results on May 12, 2022

SenesTech, Inc., Annual General Meeting, Jun 23, 2022

Price target decreased to US$4.00

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.56 loss in 3Q 2020)

We Think SenesTech (NASDAQ:SNES) Needs To Drive Business Growth Carefully

Consensus forecasts updated

Independent Director recently bought US$229k worth of stock

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.59 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.22 loss per share (vs US$1.70 loss in 1Q 2020)

Forecast to breakeven in 2025

Full year 2020 earnings released: US$2.64 loss per share (vs US$7.69 loss in FY 2019)

SenesTech, Inc. to Report Q4, 2020 Results on Mar 25, 2021

New 90-day high: US$2.28

SenesTech, Inc. announced that it has received $10.000004 million in funding

SenesTech, Inc. announced that it expects to receive $10.000004 million in funding

New 90-day high: US$1.90

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.56 loss per share

SenesTech, Inc. Restructures Board for Commercial Growth

SenesTech EPS of -$0.56

SenesTech, Inc. to Report Q3, 2020 Results on Nov 11, 2020

New 90-day low: US$1.36

Contrapest® Added to San Francisco Reduced Risk Pesticide List

SenesTech, Inc. Maps Out Plan for Increased Use of ContraPest in Integrated Pest Management in California

New 90-day low - US$1.65

Analysts update estimates

Earnings released

SenesTech, Inc. to Report Q2, 2020 Results on Aug 12, 2020

SenesTech, Inc.(NasdaqCM:SNES) dropped from Russell Microcap Index